Key Takeaways
- • EQT acquires Corza Biosurgery, a specialty medical device unit built around TachoSil, a hemostatic surgical patch used to stop bleeding and seal tissue during operations, from GTCR-backed Corza Medical.
- • The transaction brings EQT X fund deployment to 80%-85% invested; financial terms were not disclosed, with closing expected in Q4 2026 subject to customary conditions and regulatory approvals.
- • Corza Biosurgery operates a specialized manufacturing facility in Linz, Austria, and employs approximately 400 people globally; Thierry Leclercq remains as management leader with Sheri McCoy (former chair of Johnson & Johnson's Surgical Care Group) appointed as chair of the standalone entity.
- • EQT's stated growth strategy includes commercial acceleration, geographic and indication expansion, innovation investment, and platform consolidation through M&A in the broader biosurgery market.
- • Citigroup served as financial advisor to Corza Medical and GTCR on the transaction.
Summary
EQT, the Swedish private equity firm, has agreed to acquire Corza Biosurgery from GTCR-backed Corza Medical in a transaction expected to close in the fourth quarter of 2026. Corza Biosurgery is centered on TachoSil, a specialty medical patch designed to control bleeding and seal tissue during surgical procedures. The asset represents a focused entry for EQT into the surgical hemostasis and biosurgery market segment.
The acquired business operates a dedicated manufacturing facility in Linz, Austria, and maintains a global workforce of approximately 400 employees. Management continuity will be preserved with Thierry Leclercq remaining in leadership of the standalone company. The board composition will be strengthened by the appointment of Sheri McCoy, former chair of Johnson & Johnson's Surgical Care Group, as chair—bringing significant healthcare and surgical device industry expertise to the governance structure.
EQT has articulated a comprehensive value creation plan centered on four pillars: commercial acceleration to drive market penetration, expansion into new therapeutic indications and geographic markets, investment in product innovation and manufacturing capabilities, and platform building through targeted acquisitions in the broader biosurgery space. The transaction is expected to bring EQT X fund deployment to between 80% and 85% invested. Deal financial terms were not disclosed. Citigroup advised both Corza Medical and GTCR on the transaction. The acquisition remains subject to customary closing conditions and regulatory approvals.
The acquired business operates a dedicated manufacturing facility in Linz, Austria, and maintains a global workforce of approximately 400 employees. Management continuity will be preserved with Thierry Leclercq remaining in leadership of the standalone company. The board composition will be strengthened by the appointment of Sheri McCoy, former chair of Johnson & Johnson's Surgical Care Group, as chair—bringing significant healthcare and surgical device industry expertise to the governance structure.
EQT has articulated a comprehensive value creation plan centered on four pillars: commercial acceleration to drive market penetration, expansion into new therapeutic indications and geographic markets, investment in product innovation and manufacturing capabilities, and platform building through targeted acquisitions in the broader biosurgery space. The transaction is expected to bring EQT X fund deployment to between 80% and 85% invested. Deal financial terms were not disclosed. Citigroup advised both Corza Medical and GTCR on the transaction. The acquisition remains subject to customary closing conditions and regulatory approvals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.